Artesunate/amodiaquine

From Wikipedia, the free encyclopedia
  (Redirected from ASAQ)
Jump to: navigation, search
Artesunate/amodiaquine
Combination of
Artesunate Antimalarial
Amodiaquine Antimalarial
Clinical data
Trade names Coarsucam
Pregnancy cat. C (US)
Legal status ?
Identifiers
CAS number 944945-14-6 N
ATC code P01BF03
 N (what is this?)  (verify)

Artesunate/amodiaquine (trade name Coarsucam) is a fixed-dose artemisinin-based combination therapy (ACT) indicated for the treatment of acute uncomplicated Plasmodium falciparum malaria.

It was launched in 2007 as an affordable treatment for malaria, devised by DNDi in partnership with Sanofi-Aventis.[1]

The drug is patent free.[2]

Early clinical trials showed that a once-a-day dosage was effective.[3] It was subsequently clinically shown to be equally effective as artemether/lumefantrine ("Coartem"),[4] although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.

References[edit]

  1. ^ "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available".  080218 dndi.org
  2. ^ "ASAQ - The $1 Future of Malaria Treatment « GlobaLab".  080218 globalab.wordpress.com
  3. ^ Ndiaye (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. Retrieved 18 January 2013. 
  4. ^ Nidiaye. "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. Retrieved 18 January 2013. 

External links[edit]